Press releases

ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced two publications providing new nonclinical evidence and scientific insights into the ability of its novel stimulator of interferon genes (STING) agonist, IMGS-203, to remodel the tumor microenvironment and enhance antitumor activity in combination with the Company’s novel cytotoxic dual-specific PD-L1/PD-L2 antibody.

ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced upcoming presentations describing the IND-enabling activities and therapeutic potential for IMGS-203, the company’s novel Stimulator of Interferon Genes (STING) Agonist, for the treatment of recurrent glioblastoma (GBM). These data will be presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting taking place from November 4-8, 2026, at the Phoenix Convention Center in Phoenix, AZ.

Dr. Reza Mazhari has more than 25 years of life science operating experience in drug discovery, early-stage clinical development and business and corporate development across diverse therapeutic areas including oncology. Mr. Davis brings more than three decades of leadership experience guiding one of the world’s most respected sports organizations through periods of significant growth, innovation and organizational transformation.

ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced the appointment of Claudio Dansky Ullmann, M.D. as Chief Medical Officer. Dr. Dansky Ullmann will support development of the Company’s cytotoxic immune checkpoint inhibitor, IMGS-001, and ImmunoGenesis’ multi-mechanism strategy aimed at addressing the pathology of immune-excluded tumors by overcoming immune exclusion.

ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced that it will present a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026, which is being held from April 17–22, 2026, in San Diego, CA.

BostonGene, developer of the leading AI foundation model for tumor and immune biology, and ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, today announced a strategic partnership to accelerate the clinical development of IMGS-001, the company’s lead program.

IMGS-001, the company’s lead program, is a cytotoxic immune checkpoint inhibitor targeting PD-L1 and PD-L2 and is being studied in a phase 1a/b dose escalation and expansion trial (NCT06014502). The focus of this CPRIT grant – which is the Company’s second grant from CPRIT – will be to support the phase 1b dose expansion portion of the trial across multiple solid tumor cohorts.

Initial meeting of Scientific Advisory Board (SAB) convened to discuss the first-in-human phase 1a/1b clinical trial of IMGS-001, a dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies.

IMGS-001 is first dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function and is designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies.

First dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function is designed to treat the many “immune-excluded” cancers that are resistant to existing immunotherapies. Promising early signals of activity seen as Phase 1 dose escalation proceeds.